within Pharmacolibrary.Drugs.ATC.A;

model A10BB01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 2.5833333333333332e-05,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0101,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0115,
    Tlag           = 9.96,            
    Vdp             = 0.0128,
    k12             = 0.53,
    k21             = 0.53
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Glibenclamide (also known as glyburide) is a second-generation sulfonylurea used for the treatment of type 2 diabetes mellitus. It stimulates insulin secretion from pancreatic beta cells. Glibenclamide is widely approved and marketed for this indication globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers, after single oral administration, sexes combined.</p><h4>References</h4><ol><li><p>Bin Jardan, YA, et al., &amp; Al-Jenoobi, FI (2021). Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. <i>Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society</i> 29(7) 719–723. DOI:<a href=\"https://doi.org/10.1016/j.jsps.2021.05.002\">10.1016/j.jsps.2021.05.002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34400867/\">https://pubmed.ncbi.nlm.nih.gov/34400867</a></p></li><li><p>Jönsson, A, et al., &amp; Melander, A (2000). Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. <i>European journal of clinical pharmacology</i> 56(9-10) 711–714. DOI:<a href=\"https://doi.org/10.1007/s002280000214\">10.1007/s002280000214</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11214781/\">https://pubmed.ncbi.nlm.nih.gov/11214781</a></p></li><li><p>Harrower, AD (1996). Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. <i>Clinical pharmacokinetics</i> 31(2) 111–119. DOI:<a href=\"https://doi.org/10.2165/00003088-199631020-00003\">10.2165/00003088-199631020-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8853933/\">https://pubmed.ncbi.nlm.nih.gov/8853933</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BB01;
